This post is from a low-reputation account and contains an unverified outbound link. Be cautious before clicking external links.
One of the most common and fatal types of cancer in the world continues to be lung cancer. The most prevalent form of lung cancer, non-small cell lung cancer (NSCLC), is characterised by its heterogeneity, needing a wide variety of therapeutic modalities. The identification of Anaplastic Lymphoma Kinase (ALK) gene rearrangements in this context has opened the door for a ground-breaking method of therapy utilising targeted medicines.